At this ASCO annual meeting, many emerging biotechnology companies also released their latest clinical data on some new targets. #1 Junshi BTLA B and T lymphocyte attenuator (BTLA), as an immune checkpoint molecule, has similar structure and intracellular signaling mechanism with other immune ...